0 CHECKOUT

PRODUCT FILTERS

REGION

1,244
611
608
525
525

COUNTRY

510
132
82
80
79

CATEGORIES

  • 351
  • 252
  • 252
  • 240
  • 214
  • 209
  • 169
  • 159
  • 159
  • 145
  • 136
  • 135
  • 98
  • 89
  • 42

PRICE

312
973
1,461
3,662

PUBLISHED

248
1,089
1,856
3,662

PRODUCT TYPE

2,885
358
252
136
26
2
1
1
1

Oncology Drugs

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015

Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics...

Published:  January 2015
Price:  From

Global Orphan Cancer Drug Market & Clinical Pipeline Insight

The drug development strategies of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to orphan drugs due to significant competition from...

Published:  June 2014
Price:  From

Cancer Cell Therapy Market & Pipeline Insight

Since the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical...

Published:  June 2014
Price:  From

Global Radiation Therapy Equipment Market 2014-2018

About Radiation Therapy Equipment Radiation therapy equipment is used to perform radiation therapy, also known as radiotherapy or radiation oncology, which is a procedure used in the treatment of cancer...

Published:  March 2014
Price:  From

Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014

The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large...

Published:  August 2014
Price:  From

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – Pipeline Forecast & Market Forecast in G8 Countries (2011 – 2020)

The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential with increasing incidence rate of the disease across the globe The incidence of acute lymphocytic/lymphoblastic...

Published:  December 2013
Price:  From

Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the Treatment Paradigm of Prostate Cancer

XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting? Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry In recent...

Published:  February 2014
Price:  From

Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favourable outcomes recently New targets have been validated in this process where kinases...

Published:  August 2013
Price:  From

Oncology Drug Funding 2013

A Comprehensive Intelligence Report on Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid...

Published:  September 2013
Price: 

Peripheral Lung Cancer - Pipeline Insights, 2016

The “Peripheral Lung Cancer - Pipeline Insights, 2016”, report provides comprehensive insights into pipeline drugs across this indication. A key objective of the report is to establish the understanding...

Published:  March 2016
Price:  From

Temsirolimus - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Pazopanib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Pioglitazone - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Imatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Capecitabine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Exemestane - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Vandetanib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Sunitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Erlotinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 

Lapatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent,...

Published:  May 2016
Price: 
Loading Indicator

Our Clients